Form 4: Amicus Therapeutics Executive Chairman John F. Crowley Sells Shares

John F. Crowley, Executive Chairman of Amicus Therapeutics, sold 29,181 shares of common stock at an average price of $13.3492 on March 1, 2024, according to a Form 4 filing with the SEC.

Summary

• On March 1, 2024, John F. Crowley, the Executive Chairman of Amicus Therapeutics, sold 29,181 shares of common stock.
• The sale was executed at a weighted average price of $13.3492 per share, with individual transaction prices ranging from $13.04 to $13.58.
• Following the transaction, Crowley directly owns 573,478 shares of Amicus Therapeutics common stock.
• Crowley also indirectly owns 64,895 shares through a trust.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 6, 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment towards the company's prospects.

Industry Context

Executive stock sales are a common occurrence and are often scrutinized by investors for insights into management's perspective on the company's future prospects. Rule 10b5-1 plans allow insiders to sell shares over a predetermined period, mitigating concerns about trading on non-public information.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, potentially causing a slight decrease in stock price due to increased supply.

Key Dates